ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1573

Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study

Yu Asanuma1, Yuki Shimada2, Yoshimi Aizaki1, Kazuhiro Yokota1, Noritsune Kouzu3, Yoshitake Takebayashi4, Hisashi Noma4, Shinichi Kawai5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Saitama Medical University, Saitama, Japan, 3Kouzu Orthopaedic Clinic, Chiba, Japan, 4The Institute of Statistical Mathematics, Tokyo, Japan, 5Div of Rheum/dept of Int Med, Toho Uni Sch of Med, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, joint damage and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Pentraxin 3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Plasma PTX3 level is recognized as a marker that responds to local inflammation. PTX3 stimulates osteoclastogenesis by increasing osteoblast RANKL production in vitro. PTX3 is strongly expressed in human atherosclerotic plaque, and plasma PTX3 concentration increases in patients with atherosclerotic cardiovascular disease such as unstable angina pectoris and myocardial infarction. Rheumatoid arthritis (RA) is a chronic inflammatory disorder, which is known to develop joint damage and atherosclerosis. We examined the hypotheses that the PTX3 concentrations are elevated in patients with RA and are associated with 3-year progression of joint destruction and subclinical atherosclerosis.

Methods: Plasma PTX3 concentrations were measured in 72 female patients with RA and 80 healthy control. The patients were also evaluated with respect to their clinical characteristics, joint damage, atherosclerosis and medications. Radiographs of the hands and feet were evaluated using the van der Heijde modified Sharp scoring method at baseline and at 3 years in patients with RA. We also performed carotid ultrasonography to measure subclinical atherosclerosis at the two time points in RA patients. Among female patients with RA, we investigated whether plasma PTX3 levels were associated with the progression of joint destruction and carotid intima media thickness (IMT), a surrogate marker of atherosclerosis during 3 years of follow-up.

Results:

Plasma PTX3 levels were significantly higher in female patients with RA (4.05±2.91 ng/mL) compared to healthy females (1.61±1.05 ng/mL) (Wilcoxon’s rank sum test: P<0.001). Follow-up imaging of articular radiographs and carotid ultrasonography were not obtained from 10 and 8 patients, respectively. Progression of joint damage was observed in 72.6% out of 62 patients during 3 years. Incident plaque was observed in 45% patients (40 out of 64) without baseline plaque. IMT progression was detected in 34 (53%) out of 64 patients. By multivariate analysis using multiple linear regression model for the RA patients, baseline plasma PTX3 levels were significantly associated with total Sharp score (P=0.004), erosion score (P=0.002) and joint space narrowing score (P=0.031) after 3 years follow-up with adjustment for baseline score of joint damage, age, BMI, rheumatoid factor, DAS28-ESR4, postmenopausal, use of biologics. Besides, PTX3 did not predict 3-year carotid artery IMT progression nor incident plaque in RA.

Conclusion: Female patients with RA have increased concentrations of PTX3 compared with control subjects. PTX3 was significantly associated with radiographic progression of joint damage but not with carotid atherosclerosis in RA.


Disclosure: Y. Asanuma, None; Y. Shimada, None; Y. Aizaki, None; K. Yokota, None; N. Kouzu, None; Y. Takebayashi, None; H. Noma, None; S. Kawai, None; T. Mimura, None.

To cite this abstract in AMA style:

Asanuma Y, Shimada Y, Aizaki Y, Yokota K, Kouzu N, Takebayashi Y, Noma H, Kawai S, Mimura T. Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/plasma-pentraxin-3-concentration-is-associated-with-progression-of-radiographic-joint-damage-but-not-with-carotid-atherosclerosis-in-female-patients-with-rheumatoid-arthritis-results-from-a-3-year-pr/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-pentraxin-3-concentration-is-associated-with-progression-of-radiographic-joint-damage-but-not-with-carotid-atherosclerosis-in-female-patients-with-rheumatoid-arthritis-results-from-a-3-year-pr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology